chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Had all the vaccines, still got the shingles/Suspected vaccination failure; Still got the shingles; 4 months later the itching was worse than at the beginning; Pain was very little; Patient had stretched like a dog with fleas for 4 months.; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles, itching, pain and feeling abnormal. On an unknown date, the outcome of the vaccination failure, shingles, itching and pain were unknown and the outcome of the feeling abnormal was recovered/resolved.   It was unknown if the reporter considered the vaccination failure, shingles, itching, pain and feeling abnormal to be related to Shingles vaccine.     Additional Information: GSK Receipt Date: 20-JUN-2022 Reporter's Comments: This case was reported by a consumer via interactive digital media. The patient had all the vaccines, still got the shingles, and 4 months later the itching was worse than at the beginning.  The patient was fortunate as far as pain, had very little but had stretched like a dog with fleas for 4 months. Additional Supportive Information: This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting.
Dizziness, lightheadedness, mild sob. BP 137/71, HR76, O2sat 100% RA. Nonlabored respiration. Denies headache, chest pain.
pt recvd vax 26JAN95 & 4FEB95 exp body aches, elevated temp & rash; pt seen by MD & was advised adverse react to MMR:
BONES ARE HURTING; FEVER; This spontaneous report received from a consumer via a company representative concerned a female of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the patient experienced fever, and bones are hurting. Laboratory data (dates unspecified) included: Body temperature (NR: not provided) 99. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the fever and bones are hurting was not reported. This report was non-serious.
The vaccine thawed on 13-Nov-2022 and administered on 7-Feb-2023 past 30 day BUD; No adverse event; Thaw date on 13-Nov-2022 and administered thru 7-Feb-2023 providing information on product stability for products in the fridge past the 30 day BUD; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Thaw date on 13-Nov-2022 and administered thru 7-Feb-2023 providing information on product stability for products in the fridge past the 30 day BUD), PRODUCT STORAGE ERROR (The vaccine thawed on 13-Nov-2022 and administered on 7-Feb-2023 past 30 day BUD) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 019H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 07-Feb-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 07-Feb-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Thaw date on 13-Nov-2022 and administered thru 7-Feb-2023 providing information on product stability for products in the fridge past the 30 day BUD). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vaccine thawed on 13-Nov-2022 and administered on 7-Feb-2023 past 30 day BUD) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Thaw date on 13-Nov-2022 and administered thru 7-Feb-2023 providing information on product stability for products in the fridge past the 30 day BUD), PRODUCT STORAGE ERROR (The vaccine thawed on 13-Nov-2022 and administered on 7-Feb-2023 past 30 day BUD) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Thaw date on 13-Nov-2022 and administered thru 7-Feb-2023 providing information on product stability for products in the fridge past the 30 day BUD) and PRODUCT STORAGE ERROR (The vaccine thawed on 13-Nov-2022 and administered on 7-Feb-2023 past 30 day BUD).    No concomitant medications were provided. No treatment medication was provided.
I have experienced Myocarditis symptoms; This is a spontaneous report from a contactable consumer (patient). A 31-years-old male patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for Injection, Batch/Lot Number: ER8729), via an unspecified route of administration, in left arm on 19May2021 16:00 (04:00 PM) (at the age of 31-year-old) as dose 2, single for COVID-19 immunization. The patient medical history was not reported. Patient had no Known allergies. The patient concomitant medication included omeprazole. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient previously took first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for Injection, Batch/Lot Number: ER8733), via an unspecified route of administration on 14Apr2021 16:00 (04:00 PM) (at the age of 31-year-old) as dose 1, single for COVID-19 immunization. The patient experienced myocarditis symptoms since a week after the second dose of the Pfizer vaccine on and off on an unspecified date. Patient was still experiencing them 7 weeks after his second dose. Adverse event resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive treatment for the event. Since the vaccination, the patient has not been tested for COVID-19. Outcome of the event was not resolved.   Information on Lot/Batch number was available, additional information has been requested.
I had no trouble at all with the regular flu shot 3 weeks ago.  With the H1N1 vaccination I noticed photosensitivity in 30 to 40 minutes.  By the following morning had developed skin itching and burning, numbness, electrical shocking sensations, vertigo, unusual muscle cramping, mildly swollen hands and feat, mild chills, mild nausea, foggy consciousness, and severe fatigue.  A very different experience than the seasonal vaccination 3 weeks prior.
This spontaneous case was reported by a physician and describes the occurrence of VERTIGO (Vertigo), VACCINATION COMPLICATION (Reacted pretty significantly), FEELING ABNORMAL (Felt a little funky), FATIGUE (Tired) and PYREXIA (Had a feeling like she was going to have a fever) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     NO Medical History Information was reported.     On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VERTIGO (Vertigo), VACCINATION COMPLICATION (Reacted pretty significantly), FEELING ABNORMAL (Felt a little funky), FATIGUE (Tired) and PYREXIA (Had a feeling like she was going to have a fever). At the time of the report, VERTIGO (Vertigo), VACCINATION COMPLICATION (Reacted pretty significantly), FEELING ABNORMAL (Felt a little funky), FATIGUE (Tired) and PYREXIA (Had a feeling like she was going to have a fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant Concomitant medications were reported.   No Treatment information for the event was provided.    This case was linked to MOD-2021-214611 (Patient Link). This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 09-Jun-2021 and was forwarded to Moderna on 09-Jun-2021.    This spontaneous case was reported by a physician and describes the occurrence of VERTIGO (Vertigo), VACCINATION COMPLICATION (Reacted pretty significantly), FEELING ABNORMAL (Felt a little funky), FATIGUE (Tired) and PYREXIA (Had a feeling like she was going to have a fever) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     NO Medical History Information was reported.     On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VERTIGO (Vertigo), VACCINATION COMPLICATION (Reacted pretty significantly), FEELING ABNORMAL (Felt a little funky), FATIGUE (Tired) and PYREXIA (Had a feeling like she was going to have a fever). At the time of the report, VERTIGO (Vertigo), VACCINATION COMPLICATION (Reacted pretty significantly), FEELING ABNORMAL (Felt a little funky), FATIGUE (Tired) and PYREXIA (Had a feeling like she was going to have a fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant Concomitant medications were reported.   No Treatment information for the event was provided.    This case was linked to MOD-2021-214611 (Patient Link).
Patient is fully vaccinated for COVID-19 and tested positive for COVID-19 on 8/9/21. The patient had complained of a 4 day history of nasal congestion, dry cough, and mild body aches prior to testing positive.
Pt fainted after injection, low blood pressure, low heart rate. After 15-20 min. pt was fine. When the patient received his HVP vaccination, he had an episode of syncope with brief LOC, fell and hit face with no lac/mild contusion only and vital signs following syncope showed bradycardia to the 50s and hypotension to 80s over 40s which persisted for approximately 8 minutes. Hypotension/bradycardia initially concerning for vaccination triggered anaphylaxis but given its full resolution within 10 minutes and blood pressures and heart rate increasing back to the 130s over 80s with heart rate in the 80s to 90s with none of the other accompanying features of anaphylaxis including no wheezing, no lip swelling, no vomiting, no rashes, we think that this is much more likely to be vasovagal reaction to a painful stimulus like vaccination. Patient had a similar episode of syncope when he had a splinter removal several years prior, lending further evidence to this being a vasovagal reaction. However given family concern we are happy to refer to Allergy and Immunology to see whether a skin test for HPV vaccine produces any local reaction that would indicate patient has an allergy to this important vaccine. We recommended that the patient have any painful procedures like splinter removal, vaccination, suturing etc done sitting or lying down in a safe position where syncope will not produce a fall. Patient sustain only mild left facial contusion which was improved by applying ice pack for 15 minutes. Neurologic exam following the incident indicated that the patient was articulate speaking in full sentences with normal facial neurologic exam, normal strength, normal gait and otherwise reassuring overall appearance following the episode.
had it, last time after second shingles shot/ suspected vaccination failure; had it 10 times so far, shingles; postherpetic neuralgia/ was very painful; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles and post herpetic neuralgia. The patient was treated with antivirals nos (Antiviral (Drug Name Unknown)). On an unknown date, the outcome of the vaccination failure and post herpetic neuralgia were unknown and the outcome of the shingles was recovered/resolved.   It was unknown if the reporter considered the vaccination failure, shingles and post herpetic neuralgia to be related to Shingles vaccine and Shingles vaccine.  Additional details were provided as follows: The patient self-reported this case. The age at vaccination was not reported. The patient had it 10 times so far. The last time the patient had it was after the second shingles shot.  The patient had been taking one of the antiviral drugs for over a year and still had gotten them.  The patient had been shingles free for a month now and was keeping fingers and toes crossed.  The patient stated that he/she would not wish it on anyone.  The patient also ended up with post herpetic neuralgia which was also extremely painful. The patient stated that the shots were expensive but all should try to get them.  The patient also asked why they were not covered by Medicare. This case was considered as suspected vaccination failure since the details regarding time to onset and laboratory test confirming shingles were unknown at the time of reporting. The follow-up would not possible as no contact details were available.
pt recvd 3 doses of Engerix-B & is reported as being a non-responder;
15cm X 8cm raised wheal, inflammed lower left thigh, no treatment. Resolved after 7 days.
Intermittent fevers occurring for at least 17 days after vaccination (she was seen 17 days later). No treatment given.
Pt devel red welts (5-10cm) & itching @ inject site p/receiving the flu vax;
03/15/2021: Presented to the emergency department for atypical chest pain and GERD. Patient admitted for observation and discharged the next day. Troponin was negative three times, and heartburn resolved with GI cocktail.
Fever next day of 101. Lot of pain all over. Skin felt like it was burning. Left arm was swollen and red. Felt nausea, achy, feverish and nausea for five days. Had fever for three days. Lasted for six days.  Had 2nd Shingrix on 11/7/2020. Still does not fell great. It's been nine days. Had fever of 101, had severe pain, right arm swollen ans itchy rash, nausea, diarrhea and headache. Rash moved everyday from outside of arm to inside of arm. Now it's under the arm and itchy. Feel like she does not have energy. Feels like she has the flu.
Back of Rt arm swollen, red, >golf ball.  c/o burning & itching.  Started sx last night.  Informed can use Benadryl lrg & topical.  If gets worse go to ER or clinic.  F/u Monday with Dr.  1/7/08 spoke with g-mother, doing fine.  Arm much better.
Fever (102), chills, headache, severe arm pain and erythema at site.
Patient developed a red itchy rash starting on her torso on day 5 after vaccination. Rash was itchy and not blistering. It was over a holiday weekend and patient does not have a primary care physician. Patient called nurse line on Monday and was instructed to treat itching with oral BENADRYL and topical hydrocortisone which was providing some relief, but when I spoke with her Monday she complained of being too drowsy so I recommended changing to oral cetirizine and topical diphenhydramine. Patient reported later in the day that she was getting better relief from this regimen. By Tuesday PM rash had resolved on back and was now only on extremities. I spoke with GSK medical information line who said this was consistent with SHINGRIX ADR. They said while GSK did not have an official recommendation for if patient should receive 2nd dose in series, CDC guidelines recommend patients do unless they have a level 3 or higher reaction, and that a reaction to 1st dose does not necessarily mean they will react to 2nd.
SEVERE LEFT LEG CRAMP; PAIN IN LEFT ARM LYMPH NODES; PAIN IN LEFT ARM; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 042A21A, expiry: UNKNOWN) dose was not reported, administered on 06-APR-2021 for prophylactic vaccination. Concomitant medications included acetylsalicylic acid, and paracetamol. On 25-APR-2021, the subject experienced severe left leg cramp. On 25-APR-2021, the subject experienced pain in left arm lymph nodes. On 25-APR-2021, the subject experienced pain in left arm. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the severe left leg cramp, pain in left arm and pain in left arm lymph nodes was not reported. This report was non-serious.
pain in arm w/weakness on exam, tingling, paresthesia of forearm;seen on 28AUG95;unk onset of sx;now also exp weakness in legs;no tx @ this time;20OCT95: no addtl info provided on f/u;
Moderna COVID-19 Vaccine EUA  Hand went numb the day of the injection, improved within half hour after injection. 1/10/21  Headache, 1/12/21
Hot, diaphoretic, lightheaded Narrative:  felt lightheaded, dizziness, layed down, at 12:18 VS HR 78, BP 110/73, RR24, 12:28 HR 85, BP 129/92, RR12, 12:39 HR 70, BP 124/85, RR 14, felt better after H2O, pt left with sx resolved at12:39
Warm to the touch; Big Red Spot on Injection Site (The Size of a Large Orange); This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Warm to the touch) and VACCINATION SITE ERYTHEMA (Big Red Spot on Injection Site (The Size of a Large Orange)) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Feb-2021, the patient experienced VACCINATION SITE WARMTH (Warm to the touch) and VACCINATION SITE ERYTHEMA (Big Red Spot on Injection Site (The Size of a Large Orange)). At the time of the report, VACCINATION SITE WARMTH (Warm to the touch) and VACCINATION SITE ERYTHEMA (Big Red Spot on Injection Site (The Size of a Large Orange)) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.  No treatment information was provided.
This spontaneous report as received from a male patient who was also a physician of 65 years ago regarding himself. Current conditions and medical history was reported as none. On an unknown date in 2010(reported as 4 years ago), the patient had received PNEUMOVAX 23 vial, 0.5 milliliters (ml), intramuscular in the left arm. On 08-NOV-2014, the patient was received with PNEUMOVAX 23. Concomitant medications were reported as none. On an unknown date approximately in November 2014, the patient reported that he had developed injection site reaction which was described as injection site discomfort. Patient stated that he was using TYLENOL for the discomfort. No lab diagnostics studies performed. The outcome was reported as not recovered. Causality assessment was not reported. Product quality complaint was not reported. This is one of the 2 reports reported by same reporter. Additional information has been requested.
Five mins after receiving vaccines, pt started vomiting clear fluid mixed with mucous then started complaining of severe abdominal pain. He then became flushed and developed hives with severe pruritis. Given Benadryl and Prednisone then the symptoms resolved approximately 20 mins after.
Felt dizzy and weak immediately following. Later in day, developed itching and hives. Benedryl given per phone conversation.
Dizziness; Fever; Confused; Discomfort in joints; Motor cycling accident; This spontaneous case was reported by a consumer and describes the occurrence of ROAD TRAFFIC ACCIDENT (Motor cycling accident), DIZZINESS (Dizziness), MUSCULOSKELETAL DISCOMFORT (Discomfort in joints), PYREXIA (Fever) and CONFUSIONAL STATE (Confused) in a 29-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate free. In May 2021, the patient experienced ROAD TRAFFIC ACCIDENT (Motor cycling accident) and MUSCULOSKELETAL DISCOMFORT (Discomfort in joints). On an unknown date, the patient experienced DIZZINESS (Dizziness), PYREXIA (Fever) and CONFUSIONAL STATE (Confused). At the time of the report, ROAD TRAFFIC ACCIDENT (Motor cycling accident) and MUSCULOSKELETAL DISCOMFORT (Discomfort in joints) had not resolved and DIZZINESS (Dizziness), PYREXIA (Fever) and CONFUSIONAL STATE (Confused) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medicine were provided. There was no reported medical history. For HUMIRA, the reporter causality for the events of Motorcycle accident was no reasonable possibility and for the events of Dizziness, Discomfort in wrist, Fever and Confused was not provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in. No treatment medicine were provided.   Reporter did not allow further contact
redness; hardness; arm swollen; warm to touch; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE ERYTHEMA (redness), INJECTION SITE INDURATION (hardness), INJECTION SITE SWELLING (arm swollen) and INJECTION SITE WARMTH (warm to touch) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INJECTION SITE ERYTHEMA (redness), INJECTION SITE INDURATION (hardness), INJECTION SITE SWELLING (arm swollen) and INJECTION SITE WARMTH (warm to touch). At the time of the report, INJECTION SITE ERYTHEMA (redness), INJECTION SITE INDURATION (hardness), INJECTION SITE SWELLING (arm swollen) and INJECTION SITE WARMTH (warm to touch) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No laboratory details were  provided.  No treatment medications were reported.